SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

10 Nov 2021 Evaluate
A decent increase of about 46.73% in the sales to Rs. 5749.97 millions was observed for the quarter ended September 2021. The sales figure stood at Rs. 3918.69 millions during the year-ago period.The Net Profit of the company reported a remarkable increase of 110.67% to Rs. 185.18  millions  from Rs. 87.90 millions in previous same quarter.The company reported a good operating profit of 693.74 millions compared to 521.56 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 5749.97 3918.69 46.73 10837.87 8028.82 34.99 18575.66 16919.32 9.79
Other Income 224.10 452.58 -50.48 340.96 688.30 -50.46 1170.85 930.71 25.80
PBIDT 693.74 521.56 33.01 863.10 953.39 -9.47 2763.16 2975.28 -7.13
Interest 180.03 144.71 24.41 360.94 303.00 19.12 653.39 668.43 -2.25
PBDT 513.71 376.85 36.32 502.16 650.39 -22.79 2109.77 2306.85 -8.54
Depreciation 270.89 249.72 8.48 537.25 494.62 8.62 993.42 942.40 5.41
PBT 242.82 127.13 91.00 -35.09 155.77 -122.53 1116.35 1364.45 -18.18
TAX 57.64 39.23 46.93 -7.96 59.00 -113.49 333.95 161.70 106.52
Deferred Tax 57.64 5.49 949.91 -7.96 14.51 -154.86 123.77 9.70 1175.98
PAT 185.18 87.90 110.67 -27.13 96.77 -128.04 782.40 1202.75 -34.95
Equity 897.77 896.26 0.17 897.77 896.26 0.17 896.80 895.70 0.12
PBIDTM(%) 12.07 13.31 -9.35 7.96 11.87 -32.94 14.88 17.59 -15.41

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×